Livanova hits goals in sleep apnea implant trial, plans FDA filing
1 day ago · Dive Brief: Livanova said Monday a trial of its obstructive sleep apnea (OSA) implant met its primary safety and efficacy endpoints, positioning the company to seek approval once …
LivaNova nerve stim for sleep apnea meets study endpoints
2 days ago · November 11, 2024 By Sean Whooley. LivaNova (Nasdaq:LIVN) today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary endpoints. …
New Drug Offers Hope for CPAP-Free Nights for Sleep Apnea - WebMD
May 30, 2024 · Could there be a new approach – a simple pill – that eases sleep apnea symptoms and replaces more conventional treatments? That’s what researchers at Apnimed …
LivaNova Announces OSPREY Clinical Study Meets Primary Safety …
3 days ago · LONDON -- (BUSINESS WIRE)--Nov. 11, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it met the primary …
FDA Clears First Oral Appliance for Severe Sleep Apnea
Dec 19, 2023 · For the first time, the Food and Drug Administration (FDA) cleared oral devices that treat severe obstructive sleep apnea (OSA). These devices offer an alternative to more …
Eli Lilly expects FDA call on Zepbound for sleep apnea in near term
Jun 21, 2024 · If cleared by the Food and Drug Administration, the company plans to launch Zepbound for so-called obstructive sleep apnea "as quickly as we can" at the beginning of …
Tirzepatide reduced sleep apnea severity by up to nearly two …
Apr 17, 2024 · Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity. Tirzepatide achieved a mean apnea-hypopnea …
CPAP replacement works well for the overweight, not obese, study ... - CNN
Apr 4, 2024 · An implantable, FDA-approved device for obstructive sleep apnea — designed to replace a CPAP — works best for people who aren’t too overweight, a new study finds.
FDA Authorizes Marketing of Novel Device to Reduce Snoring and …
Feb 5, 2021 · Today, the U.S. Food and Drug Administration authorized marketing of a new prescription only device intended to reduce snoring and mild obstructive sleep apnea.
FDA Clears Vivos CARE Appliance for Severe Obstructive Sleep Apnea
Dec 5, 2023 · Recently, the FDA granted 510 (k) clearance to Vivos Therapeutics for its removable CARE (Complete Airway Repositioning and/or Expansion) oral appliances as a …